文献速递消化系统肿瘤

二甲双胍与胰岛素对索拉非尼治疗晚期肝细胞癌患者临床结局的影响:验证性研究及生物学机制

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
PubMed 文献 · Eur J Cancer · 2017-10-03

本研究验证二甲双胍对索拉非尼治疗肝细胞癌患者预后意义。分析279例患者,其中86例(30%)患2型糖尿病,52例(19%)长期用二甲双胍,34例(12%)用胰岛素。二甲双胍组PFS和OS分别为1.9和6.6个月,显著差于无糖尿病组(3.7和10.8个月)和胰岛素组(8.4和16.6个月)(P<.0001)。二甲双胍组SIRT-3表达显著高于非二甲双胍组(65% vs 25%,P=.013)。

要点

  • 长期二甲双胍治疗的晚期肝细胞癌患者接受索拉非尼的PFS和OS显著更差
  • 二甲双胍组SIRT-3蛋白表达显著高于非二甲双胍组
  • 二甲双胍可能通过增加肿瘤侵袭性和索拉非尼耐药性影响疗效

核心结论

  • 长期二甲双胍治疗可能与索拉非尼治疗晚期肝细胞癌患者的较差PFS和OS相关,并伴随SIRT-3表达升高。

研究设计与样本

  • 验证性研究,临床分析纳入279例连续接受索拉非尼治疗的肝细胞癌患者,其中86例(30%)患2型糖尿病,52例(19%)长期用二甲双胍,34例(12%)用胰岛素。
  • 生物学研究纳入43例肝细胞癌患者,其中19例(44.1%)患糖尿病,14例(73.7%)接受二甲双胍治疗,通过免疫组化检测FFPE样本中SIRT-3表达。

主要发现

  • 二甲双胍组PFS和OS分别为1.9个月和6.6个月,无糖尿病组分别为3.7个月和10.8个月,胰岛素组分别为8.4个月和16.6个月(P<.0001)。
  • 二甲双胍组SIRT-3蛋白表达显著高于非二甲双胍组(65% vs 25%,P=.013)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib. The aim of the present study was to validate the prognostic significance of metformin in HCC patients treated with sorafenib, providing a biological rationale for the mechanism of resistance to sorafenib in patients on chronic metformin therapy, and to clarify the role of sirtuin-3 (SIRT-3), a protein involved in metabolic diseases and acknowledged as a tumour suppressor in HCC, in this resistance. PATIENTS AND METHODS: We analysed 279 patients consecutively treated with sorafenib for the clinical analysis. Of the 86 (30%) patients with DM2, 52 (19%) were on chronic treatment with metformin and 34 (12%) with insulin. We included 43 patients with HCC for the biological study: 19 (44.1%) were diabetic and 14 (73.7%) of these received metformin for DM2. SIRT-3 expression was investigated by immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded (FFPE) samples. RESULTS: In HCC patients undergoing chronic treatment with metformin, the use of sorafenib was associated with poor progression-free survival (PFS) and overall survival (OS) (1.9 and 6.6 months, respectively) compared to 3.7 months and 10.8 months, respectively, for patients without DM2 and 8.4 months and 16.6 months, respectively, for patients on insulin (P < .0001). We also observed that SIRT-3 protein expression was significantly higher in patients treated with metformin than in those not taking this medication (65% versus 25%, respectively) (P = .013). CONCLUSIONS: Our findings could be attributed to increased tumour aggressiveness and resistance to sorafenib caused by chronic treatment with metformin.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Casadei Gardini A, Faloppi L, De Matteis S, et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Eur J Cancer. 2017. PMID: 28985579. doi:10.1016/j.ejca.2017.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。